JP2022537385A5 - - Google Patents

Info

Publication number
JP2022537385A5
JP2022537385A5 JP2021575515A JP2021575515A JP2022537385A5 JP 2022537385 A5 JP2022537385 A5 JP 2022537385A5 JP 2021575515 A JP2021575515 A JP 2021575515A JP 2021575515 A JP2021575515 A JP 2021575515A JP 2022537385 A5 JP2022537385 A5 JP 2022537385A5
Authority
JP
Japan
Prior art keywords
cancer
crystalline polymorph
powder
ray diffraction
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021575515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537385A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037892 external-priority patent/WO2020257169A1/en
Publication of JP2022537385A publication Critical patent/JP2022537385A/ja
Publication of JP2022537385A5 publication Critical patent/JP2022537385A5/ja
Withdrawn legal-status Critical Current

Links

JP2021575515A 2019-06-19 2020-06-16 大環状キナーゼ阻害剤の多形 Withdrawn JP2022537385A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962863493P 2019-06-19 2019-06-19
US62/863,493 2019-06-19
US202062959940P 2020-01-11 2020-01-11
US62/959,940 2020-01-11
US202063036102P 2020-06-08 2020-06-08
US63/036,102 2020-06-08
PCT/US2020/037892 WO2020257169A1 (en) 2019-06-19 2020-06-16 Polymorphs of a macrocyclic kinase inhibitor

Publications (2)

Publication Number Publication Date
JP2022537385A JP2022537385A (ja) 2022-08-25
JP2022537385A5 true JP2022537385A5 (cg-RX-API-DMAC7.html) 2023-06-26

Family

ID=74040102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575515A Withdrawn JP2022537385A (ja) 2019-06-19 2020-06-16 大環状キナーゼ阻害剤の多形

Country Status (15)

Country Link
US (1) US20220411439A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986413A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022537385A (cg-RX-API-DMAC7.html)
KR (1) KR20220046549A (cg-RX-API-DMAC7.html)
CN (1) CN114025765A (cg-RX-API-DMAC7.html)
AU (1) AU2020294627A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025786A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143043A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000405A2 (cg-RX-API-DMAC7.html)
IL (1) IL288982A (cg-RX-API-DMAC7.html)
MX (1) MX2021015756A (cg-RX-API-DMAC7.html)
PE (1) PE20220135A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553174A1 (cg-RX-API-DMAC7.html)
TW (1) TW202115090A (cg-RX-API-DMAC7.html)
WO (1) WO2020257169A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113336774B (zh) * 2021-06-25 2023-05-23 江南大学 作为trk抑制剂的取代的手性二芳基大环化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112806A2 (en) * 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
RU2732405C2 (ru) * 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
BR112018000297A2 (pt) * 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
WO2017015367A1 (en) * 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
CA3069554A1 (en) * 2017-07-14 2019-01-17 Glaxosmithkline Intellectual Property Development Limited Inhibitors of leucine rich repeat kinase 2
RS63787B1 (sr) * 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti

Similar Documents

Publication Publication Date Title
IL283184B2 (en) Crystal polymorph of (7s,13r)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10] benzoxatriazacyclotridecin–4(5h)–one for the treatment of cancer
HRP20191944T1 (hr) Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
JP2021512131A5 (cg-RX-API-DMAC7.html)
CN116568689B (zh) 一种作为sos1抑制剂的多环嘧啶类衍生物、其制备方法及用途
TW591030B (en) Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
RU2014124005A (ru) Комбинация инотузумаба озогамицина и торизела для лечения рака
JP2022549375A5 (cg-RX-API-DMAC7.html)
ES2263595T3 (es) Nuevos derivados aza-indolicos.
CN107304191A (zh) 吲哚胺2,3‑双加氧酶抑制剂及其制备方法与应用
RU2017141035A (ru) Твердые формы соединения, модулирующего киназы
RU2010121647A (ru) Полиморфы ингибитора c-met/hgfr
RU2013128612A (ru) Соли и кристаллические формы индуцирующего апоптоз агента
CN106883193B (zh) 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
US10745350B2 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
JP2018515490A5 (cg-RX-API-DMAC7.html)
JP2013543894A5 (cg-RX-API-DMAC7.html)
JP2007530526A5 (cg-RX-API-DMAC7.html)
RU2011148521A (ru) Соль авт-263 и ее формы в твердом состоянии
EP1490371A1 (en) Thiopene-based tricyclic compounds and pharmaceutical compositions comprising same
US11918585B2 (en) Formulations of an AXL/MER inhibitor
JP2009527533A5 (cg-RX-API-DMAC7.html)
JP2022515239A5 (cg-RX-API-DMAC7.html)
WO2023185793A1 (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
JP2014005265A5 (cg-RX-API-DMAC7.html)
JP2024519626A5 (cg-RX-API-DMAC7.html)